Cypherpunk Technologies Boosts Digital‑Asset Treasury and Leap Therapeutics’ FDA Phase‑3 Momentum
Cypherpunk Technologies posts Q2 2026 gains: $0.68 a share, expanded ZEC holdings, FDA‑aligned Phase 3 for Leap Therapeutics, and breakthrough DeFianCe results that could drive future upside.
3 minutes to read